Tarsus Pharmaceuticals (TARS) Finished Goods (2023 - 2026)

Tarsus Pharmaceuticals' Finished Goods history runs 4 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• On a quarterly basis, Finished Goods rose 51.47% year-over-year to $2.9 million in Q1 2026; TTM through Mar 2026 was $2.9 million, a 51.47% increase from a year earlier, with the FY2025 full-year figure at $3.0 million, up 47.66% from the prior year.
• Finished Goods declined to $2.9 million in Q1 2026 per TARS's latest filing, from $3.0 million in the prior quarter.
• Across five years, Finished Goods topped out at $3.0 million in Q4 2025 and bottomed at $182000.0 in Q4 2023.
• The 4-year median for Finished Goods is $2.0 million (2024), against an average of $1.8 million.
• Across the five-year window, Finished Goods surged 1002.2% in 2024 and jumped 47.66% in 2025, its largest moves.
• Year by year, Finished Goods stood at $182000.0 in 2023, then jumped by 1002.2% to $2.0 million in 2024, then jumped by 47.66% to $3.0 million in 2025, then slipped by 0.74% to $2.9 million in 2026.
• Per Business Quant, the three latest TARS Finished Goods figures stand at $2.9 million (Q1 2026), $3.0 million (Q4 2025), and $2.8 million (Q3 2025).